Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Rubius Therapeutics, Inc. RUBY NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
30/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Rubius Therapeutics, Inc. (RUBY) is a Biotechnology company in the Healthcare sector, currently trading at $0.06. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $231M (loss), growing at -13.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1M against $15M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 2.54 (strong liquidity). Debt-to-assets is 4.8%. Total assets: $23M.

Analyst outlook: 5 / 9 analysts rate RUBY as buy (56%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 40/100 (Partial), Income ?/100 (Fail).

RUBY SharesGrow Score Overview

38/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 40/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RUBY

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
RUBY: +0%/yr revenue is, -13.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet RUBY: Debt-to-Equity (D/E) ratio 0.07 (conservative), Current ratio is 2.54 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
RUBY: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
40/100
Analyst outlook: 5 / 9 analysts rate RUBY as buy (56%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.0032-0.3763
Volume755.86K
Avg Volume (30D)99.54K
Beta (1Y)2.21
Share Statistics
EPS (TTM)-2.56
Shares Outstanding$90.31M
IPO Date2018-07-18
Employees6
CEOLaurence A. Turka
Financial Highlights & Ratios
EBITDA$-118.35M
Net Income$-230.86M
Operating Income$-178.45M
Total Cash$18.94M
Total Debt$1.1M
Net Debt$-13.77M
Total Assets$23.07M
Price / Earnings (P/E)-0
Analyst Forecast
Rating ConsensusBuy
Analysts Covering9
Buy 56% Hold 33% Sell 11%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS78116T1034

Price Chart

Track all markets on TradingView
RUBY
Rubius Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.00 52WK RANGE 0.38

People Also View

SRRK
SRRK
Scholar Rock Holding Corporation
$49.53
+0.02%
 REPL
REPL
Replimune Group, Inc.
$1.95
+14.71%
 MGTA
MGTA
Magenta Therapeutics, Inc.
$0.70
-7.74%
 AVRO
AVRO
AVROBIO, Inc.
$1.40
-1.41%
 EVLO
EVLO
Evelo Biosciences, Inc.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message